Health Discovery retains Dilenschneider Group to manage its investor and media relations work

Health Discovery Corporation (OTCBB: HDVY), is pleased to announce that it has retained The Dilenschneider Group, headquartered in New York City, to manage the Company’s investor and media relations work. With offices in New York, Washington, DC and Chicago, the Dilenschneider Group provides its clients with some of the finest and most seasoned communications professionals in the world.

“We are delighted to have The Dilenschneider Group on-board to lead our newly implemented investor and media relations effort at a pivotal time in the company’s development,” said Dr. Stephen Barnhill, Chairman and CEO of Health Discovery Corporation. “The Dilenschneider Group is a highly respected corporate communications firm and we welcome their expertise to effectively communicate the Company’s exciting corporate achievements,” said Dr. Barnhill.

“We are pleased to be representing Dr. Barnhill and the Company,” said Robert Dilenschneider, Chairman of The Dilenschneider Group. “They are at the forefront in the development of an entirely new and revolutionary approach to diagnostic and personalized medicine, and we welcome this opportunity to communicate the Company’s successes,” Mr. Dilenschneider said.

HDC recently entered into royalty-bearing licenses for its new urine-based prostate cancer test to Quest Diagnostics Incorporated (NYSE: DGX) and Abbott Laboratories (NYSE: ABT) for development and commercialization. HDC also entered into royalty-bearing licenses for its tissue biopsy-based prostate cancer test with Abbott Laboratories (NYSE: ABT) and Clarient Inc. (Nasdaq: CLRT) for development and commercialization. HDC has also partnered with Pfizer Inc. (NYSE: PFE) for use of HDC’s SVM and SVM-RFE pattern recognition technology.

A scientific paper on the association of these four genes with prostate cancer was recently published in the peer-reviewed journal, UroToday International, in its August 2009 issue. The combined results of the double-blind clinical validation studies demonstrated that the new gene-based molecular diagnostic test for prostate cancer achieved a Sensitivity of 90% for correctly identifying the presence of Grade 3 or higher prostate cancer cells, and a Specificity of 97% for correctly identifying non-cancer cells (normal and BPH), representing an overall test accuracy of 93%.

HDC’s new prostate cancer tests are based on a unique and patent protected combination of four genes that have been shown to accurately identify the presence of Grade 3 or higher prostate cancer cells in prostate tissue and urine. The association of these four genes with prostate cancer was discovered by Health Discovery Corporation using their patented SVM and SVM-RFE pattern recognition technology.